A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's Disease

NCT00146211 Phase 3 COMPLETED

This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.

Details

Lead sponsor	Amarin Neuroscience Ltd
Phase	Phase 3
Status	COMPLETED
Enrolment	300
Start date	2005-09
Completion	2007-07

Conditions

• Huntington Disease

Interventions

• Ethyl-EPA (Miraxion™)

Primary outcomes

• To compare with placebo the effect of ethyl-EPA on the Total Motor Score-4 component (TMS) of the Unified Huntington's Disease Rating Scale (UHDRS) over a 6-month period of observation.

Countries

United States, Canada